Biochemistry, Genetics and Molecular Biology · Medicine
| ISSN | 24682942 |
|---|---|
| Country | United Kingdom |
| Publisher | Elsevier Ltd. |
| Subject Areas | Biochemistry, Genetics and Molecular Biology · Medicine |
| Publication Type | Journals |
| Active Years | 2016-2021 |
| Website | Visit journal |
From January 2020 Cancer Treatment and Research Communications is an open access journal. Authors who publish in Cancer Treatment and Research Communications will be able make their work immediately permanently and freely accessible. Cancer Treatment and Research Communications authors will pay an article publishing charge APC have a choice of license options and retain copyright to their published work.Cancer Treatment and Research Communications is an international peerreviewed publication dedicated to providing comprehensive basic translational and clinical oncology research. The journal is devoted to articles on detection diagnosis prevention policy and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology with an emphasis on prospective early phase clinical trials.Specific areas of interest include basic translational and clinical research and mechanistic approaches cancer biology molecular carcinogenesis genetics and genomics stem cell and developmental biology immunology molecular and cellular oncology systems biology drug sensitivity and resistance gene and antisense therapy pathology markers and prognostic indicators chemoprevention strategies multimodality therapy cancer policy and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
| Year | 2-Year IF | 3-Year IF | 4-Year IF |
|---|---|---|---|
| 2023 | 2.491 | 2.444 | 2.452 |
| 2022 | 2.517 | 2.555 | 2.438 |
| 2021 | 1.985 | 1.877 | 1.707 |
| 2020 | 1.587 | 1.435 | 1.128 |
| 2019 | 0.517 | 0.632 | 0.657 |
| 2018 | 0.593 | 0.529 | 0.527 |
| 2017 | 0.431 | 0.462 | 0.451 |
| 2016 | 0.367 | 0.338 | 0.338 |
| 2015 | 0.308 | 0.308 | 0.308 |
| 2014 | 0.200 | — | — |
Note: impact factor data for reference only.
SJR measures scientific influence, weighting citations by the prestige of the citing journal.
| Year | SJR Score |
|---|---|
| 2023 | 0.793 |
| 2022 | 0.674 |
| 2021 | 0.520 |
| 2020 | 0.459 |
| 2019 | 0.256 |
| 2018 | 0.297 |
| 2017 | 0.250 |
| 2016 | 0.182 |
| 2015 | 0.113 |
The H-Index measures both the productivity and citation impact of a journal's publications.
| Year | H-Index |
|---|---|
| 2023 | 23.000 |
| 2022 | 18.000 |
| 2021 | 13.000 |
https://www.journals.elsevier.com/cancer-treatment-and-research-communications,https://www.elsevier.com/journals/cancer-treatment-and-research-communications/2468-2942/guide-for-authors